期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 174, 期 22, 页码 3898-3913出版社
WILEY
DOI: 10.1111/bph.13818
关键词
-
资金
- British Heart Foundation [PG/12/81/29897, RE/13/5/30177]
- European Commission Marie Sklodowska-Curie Individual Fellowships [661369]
- EPSRC [EP/L014165/1]
- Tenovus Scotland PROJECT [S15/24]
- COST (European Cooperation in Science and Technology) part of the EU [BM1404]
- Marie Curie Actions (MSCA) [661369] Funding Source: Marie Curie Actions (MSCA)
- British Heart Foundation [PG/12/81/29897] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [EP/L014165/1] Funding Source: researchfish
- EPSRC [EP/L014165/1] Funding Source: UKRI
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore, the theoretical potential to manipulate the inflammatory response to prevent cardiovascular events. However, extrapolation to humans requires care and we still lack definitive evidence to show that interfering in immune-inflammatory processes may safely lessen clinical atherosclerosis. In this review, we discuss key therapeutic targets in the treatment of vascular inflammation, placing basic research in a wider clinical perspective, as well as identifying outstanding questions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据